Clinical Trials on Adenocarcinomas

Total 9357 results

H. Lee Moffitt Cancer Center and Research Institute
Aventis Pharmaceuticals

Terminated

Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation.

Esophageal Adenocarcinomas | Adenocarcinomas of the Gastroesophageal Junction

United States
Accelerated Community Oncology Research Network
Amgen

Terminated

Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma

Gastroesophageal Adenocarcinoma | Adenocarcinomas of the Gastroesophageal Junction | Adenocarcinoma of the Distal Esophagus | Adenocarcinoma of the Proximal Stomach

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas

Gastrointestinal Adenocarcinomas

United States
University of Lausanne Hospitals

Completed

Prospective Evaluation of the Role of MRI in the Perioperative Management of Pancreas Adenocarcinomas

Pancreas Adenocarcinomas

Switzerland
National University Hospital, Singapore

Recruiting

Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)

Adenocarcinomas | Recurrent Gynecological

Singapore
Pfizer

Terminated

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Gastrointestinal Tumors | Esophageal Adenocarcinomas | Colorectal Adenocarcinomas | Gastric Adenocarcinomas

United States, Australia, Japan
Groupe Hospitalier Paris Saint Joseph

Withdrawn

Retrospective Analysis of the Expression of the Neurotensin Receptor by Metastatic Lung Adenocarcinomas (NTS)

Metastatic Lung Adenocarcinomas
Centre Hospitalier Saint Joseph Saint Luc de Lyon

Completed

Prevalence of Pancreatic Anomalies of Patients With a 1st Degree Familial History of Pancreatic Adenocarcinoma (PAPAFA)

Prevalence of Pancreas Adenocarcinomas

France
University Hospital, Strasbourg, France

Recruiting

Biomoleculars Markers of Sensitivity to Pre- and Post-operative Chemotherapy of Gastric and Cardia Adenocarcinomas: a Pilot Study

Gastric and Cardia Adenocarcinomas

France
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Active, not recruiting

Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

Colorectal Adenocarcinoma | Microsatellite Stable (MSS) Colorectal Adenocarcinomas

United States
National Center for Tumor Diseases, Heidelberg

Terminated

Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG) (HICON)

Adenocarcinomas of the Esophagogastric Junction

Germany
Criterium, Inc.
University of Colorado, Denver; Novartis

Terminated

Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Cholangiocarcinoma | Esophageal Adenocarcinoma | Colorectal Adenocarcinoma | Hepatocellular Adenocarcinoma

United States
University Hospital Tuebingen

Unknown

Study on Hyperthermic Intraperitoneal Chemotherapy After Resection of Pancreascarcinoma (PanHIPEC)

Adenocarcinomas of the Pancreas

Germany
University of Chicago

Completed

Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Weill Medical College of Cornell University
Merck Sharp & Dohme LLC; Oncolys BioPharma Inc

Not yet recruiting

Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States, Puerto Rico
Roswell Park Cancer Institute
United States Department of Defense

Recruiting

Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastroesophageal Junction... and other conditions

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Pancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...

United States
AIO-Studien-gGmbH
Servier; Institut für Klinisch-Onkologische Forschung der Krankenhaus Nordwest...

Active, not recruiting

Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer (NIFE)

Biliary Tract Cancer | Extrahepatic Bile Duct Carcinoma | Non-Resectable Hepatocellular Carcinoma | Adenocarcinoma Metastatic | Adenocarcinoma of the Biliary Tract | Adenocarinoma Locally Advanced | Intrahepatic Bile Duct Carcinoma

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

Gastroesophageal Junction Adenocarcinoma | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage II Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage IIA Esophageal... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma

United States
National Cancer Institute (NCI)

Not yet recruiting

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, The PARAMMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Metastatic Small Intestinal Adenocarcinoma | Stage III Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIA Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIB Small Intestinal Adenocarcinoma AJCC v8 | Stage IV Small Intestinal Adenocarcinoma AJCC v8

United States
Centre Leon Berard
Merck Sharp & Dohme LLC; Debiopharm International SA

Completed

Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma (CATRIPCA)

Adenocarcinoma of the Pancreas | Adenocarcinoma of the Rectum | Adenocarcinoma of the Colon

France
Weill Medical College of Cornell University
Sanofi

Completed

Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Adenocarcinoma | Distal Esophageal Adenocarcinoma

United States
Fujian Cancer Hospital

Withdrawn

Study of FMT Combined With Nivolumab in Gastric Cancer

Gastric Adenocarcinoma | Esophagus Adenocarcinoma | Esophagogastric Junction Adenocarcinoma

China
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Unresectable Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8 | Pathologic... and other conditions

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy

Stage IIIA Esophageal Adenocarcinoma | Stage IIIB Esophageal Adenocarcinoma | Stage IIIC Esophageal Adenocarcinoma | Stage IIB Esophageal Adenocarcinoma | Stage IB Esophageal Adenocarcinoma | Stage IIA Esophageal Adenocarcinoma

United States
Assistance Publique - Hôpitaux de Paris

Suspended

Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma (METIMGAST)

Gastric Adenocarcinoma | Oesophageal Adenocarcinoma

France
McGill University

Completed

Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma

Gastric Adenocarcinoma | Esophageal Adenocarcinoma

Canada
Massachusetts General Hospital

Terminated

Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma (EOXP)

Gastric Adenocarcinoma | Esophageal Adenocarcinoma

United States
OSI Pharmaceuticals

Completed

Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer

Gastric Adenocarcinoma | Gastroesophageal Adenocarcinoma

United States, United Kingdom, Belgium
UNICANCER
Canadian Cancer Trials Group

Completed

Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)

Canada, France
Astellas Pharma Global Development, Inc.

Available

Early Access Program for Zolbetuximab

Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma Cancer | Metastatic Gastric Adenocarcinoma Cancer

United States
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Active, not recruiting

Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 and other conditions

United States
Harbin Medical University

Not yet recruiting

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma
AIO-Studien-gGmbH
Taiho Pharmaceutical Co., Ltd.; Nordic Pharma SAS

Completed

Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction (S-1 adjuvant)

Adenocarcinoma,Stomach | Adenocarcinoma, Esophagogastric Junction

Germany
Blood Transfusion Centre of Slovenia

Unknown

Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma (SYSTHER)

Pancreatic Tubular Adenocarcinoma

Slovenia
Georgetown University
Genentech, Inc.; Natera, Inc.

Recruiting

Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD-GI)

Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | Gallbladder Adenocarcinoma | Adenocarcinoma of Biliary Tract

United States
Akeso

Active, not recruiting

A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
CStone Pharmaceuticals

Completed

A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
Imperial College London
Cancer Research UK

Recruiting

Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery (LABS)

Gastric Adenocarcinoma | Oesophageal Adenocarcinoma

United Kingdom
University of Wisconsin, Madison
Ipsen

Recruiting

Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma

Gastric Adenocarcinoma | Esophageal Adenocarcinoma

United States
McGill University Health Centre/Research Institute...

Recruiting

mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA)

Gastric Adenocarcinoma | Esophageal Adenocarcinoma

Canada
Milton S. Hershey Medical Center

Completed

Resilience and Exercise in Advanced Cancer Treatment (REACT)

Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Adenocarcinoma of the Gastroesophageal Junction

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm

United States
University Hospital, Akershus
Oslo University Hospital; St. Olavs Hospital

Recruiting

METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin (METIMMOX-2)

Colorectal Adenocarcinoma | Mucinous Adenocarcinoma | Signet Ring Cell Adenocarcinoma

Norway

Clinical Trials on Adenocarcinomas

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations